Prothena (NASDAQ:PRTA) Releases Earnings Results, Beats Estimates By $0.01 EPS

Prothena (NASDAQ:PRTA) issued its earnings results on Thursday. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01, Zacks reports. Prothena had a negative return on equity of 62.53% and a negative net margin of 2,520.57%.The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.67 million.

Here are the key takeaways from Prothena’s conference call:

• Roche advanced prasinezumab and Novo Nordisk advanced coramitug into Phase 3 trials (PARAISO ~900 early Parkinson’s patients; CLEOPATTRA ~1,280 ATTR‑CM patients), with primary completion expected in 2029.
• Prothena may receive up to $105 million in 2026 from partner milestones (coramitug enrollment target and BMS’s decision on PRX019), and its partnered programs have aggregate future milestone potential of roughly $3 billion plus royalties.
• The company’s novel CYTOPE technology and the TDP‑43 CYTOPE program showed preclinical CNS intracellular target engagement and aggregate clearance, prompting research collaborations with large pharma.
• Prothena finished 2025 with $308.4 million in cash and guides 2026 net cash used in operating and investing of $50–55 million, expecting approximately $255 million year‑end cash (guidance excludes the up to $105M of potential partner milestones).

Prothena Stock Up 0.6%

Shares of NASDAQ PRTA opened at $9.07 on Tuesday. The company has a market cap of $488.24 million, a P/E ratio of -2.00, a P/E/G ratio of 1.89 and a beta of -0.11. Prothena has a 52 week low of $4.32 and a 52 week high of $16.16. The business has a 50-day simple moving average of $9.24 and a two-hundred day simple moving average of $9.43.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. UBS Group set a $36.00 price target on Prothena in a research report on Tuesday, October 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Prothena in a report on Monday, December 29th. Royal Bank Of Canada raised their price target on shares of Prothena from $11.00 to $12.00 and gave the company a “sector perform” rating in a research report on Friday. Citizens Jmp set a $19.00 price target on shares of Prothena in a report on Monday, December 1st. Finally, Deutsche Bank Aktiengesellschaft set a $19.00 price objective on shares of Prothena in a research note on Monday, December 1st. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Prothena has an average rating of “Hold” and an average price target of $22.00.

Hedge Funds Weigh In On Prothena

A number of institutional investors have recently added to or reduced their stakes in the business. Intech Investment Management LLC increased its holdings in shares of Prothena by 5.5% in the 3rd quarter. Intech Investment Management LLC now owns 19,388 shares of the biotechnology company’s stock worth $189,000 after buying an additional 1,014 shares during the last quarter. Brooklyn Investment Group grew its position in Prothena by 13.1% in the third quarter. Brooklyn Investment Group now owns 12,569 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 1,456 shares in the last quarter. Deutsche Bank AG grew its position in Prothena by 5.1% in the fourth quarter. Deutsche Bank AG now owns 35,482 shares of the biotechnology company’s stock worth $339,000 after acquiring an additional 1,709 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Prothena by 3.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 81,515 shares of the biotechnology company’s stock valued at $779,000 after acquiring an additional 2,968 shares during the last quarter. Finally, Virtus Investment Advisers LLC raised its position in Prothena by 14.4% during the fourth quarter. Virtus Investment Advisers LLC now owns 25,679 shares of the biotechnology company’s stock valued at $245,000 after purchasing an additional 3,236 shares in the last quarter. 97.08% of the stock is currently owned by institutional investors.

About Prothena

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.